Taiwan's biomedical park attracts interest
This article was originally published in Clinica
Executive Summary
Construction of Taiwan's Hsinchu Biomedical Science Park is due to commence imminently. According to the department of investment services, basic facilities will be ready by June 2007, with completion scheduled for 2008-09. Planned as a major centre of R&D, industry and academia link-ups and with a functional high-tech medical centre, the park is part of Taiwan's economic reconstruction plan. The government has pledged NT$20bn (US$607m) to the project over the next five years, which it hopes will attract the interest of public and private organisations.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.